FDA Gives Three Vouchers for Faster Psychedelic Approvals

The US has given three drugmakers accelerated pathways to approval for psychedelic medications with clinical trials underway.

The groups running trials include Compass Pathways, Transcend Therapeutics and the nonprofit Usona Institute, according to a person familiar with the matter.

The Food and Drug Administration announced on Friday the drugmakers would receive national priority vouchers studying the drugs psilocybin for treatment-resistant depression and major depressive disorder and methylone for post-traumatic stress disorder. The move follows President Donald Trump’s executive order to expedite research and access to psychedelic medication to treat PTSD.

Drug companies’ interest in psychedelics is heating up. ...